Finally, we describe how the results of this study improve our understanding of the chemical basis for discriminating inhibitors from activators for ASCT2, as well as discuss the pharmacological implications of our results, including the potential use of the identified ligands as chemical tools to characterize the role of ASCT2 in cancer. This evidence concerns the gene SLC1A5 and cancer.